Federal obligations in biological product (except diagnostic) manufacturing (NAICS 325414)

Biological manufacturing versus drug preparations

NAICS 325414 covers establishments that manufacture biological products except diagnostic reagents. On USAspending.gov the code tags contract awards classified that way: vaccines, toxoids, blood products, and similar biologics production. It is not a dose count, and it is not a list of every immunization program. Diagnostic biologicals are carved out of the title and, if tagged elsewhere, do not sit in this total.

Pharmaceutical preparation manufacturing (325412) is finished-dose drugs, typically chemical preparations. Biotech R&D codes (541711, 541714) are research contracts, not licensed-product manufacturing. A countermeasure program can buy R&D under a 54171x code and doses under 325414. The $26.9 billion figure is only awards tagged 325414.

Few awards and $26.9 billion

The pairing of $26,909,128,047.49 with 1,275 awards is a concentrated biologics-production pattern: large stockpile or supply contracts rather than tens of thousands of pharmacy delivery orders. USAspending records those commitments as obligations. This packet has no fiscal-year split and no outlay total.

Outlays follow deliveries. Quote $26.9 billion as USAspending contract obligations coded to biological product (except diagnostic) manufacturing. Do not describe it as a public-health appropriation or as cash already spent. This page does not offer medical advice.

1,275 awards, not 1,275 products

The 1,275 award records include production contracts and modifications. The count is not 1,275 vaccines. Compared with pharmaceutical preparations in this industry set, biologics manufacturing shows far fewer records. Open the industry page for the award list.

Biologics manufacturing is easy to confuse with biotech research and with ordinary drug preparations. Keep the three pages apart. USAspending contract awards tagged 325414 show $26,909,128,047.49 in obligations on 1,275 awards. The except-diagnostic clause is part of the NAICS title and should ride along in any citation. Vaccines and blood products as manufacturing belong here when tagged this way. Research tagged 541711 or 541714 belongs on those R&D pages. Finished-dose chemical drugs tagged 325412 belong there. The 1,275 record count is concentrated production contracting, not a dose inventory. This page is not medical advice. Outlays and grants are not in the packet. Use the industry table for the award list.

What 325414 excludes

Assistance awards often lack NAICS and are outside this total. Physician-office contracts (621111) are clinical care, not manufacturing. Insurance-carrier contracts (524114) are plan administration. Diagnostic products, by the NAICS title, are excepted. Research tagged to 541711 or 541714 stays on those R&D pages.

SpendingVault aggregates USAspending.gov contract data. The $26,909,128,047.49 total and the 1,275 award count can change after corrections. The live industry page is the table of record.

Using the biological-product industry page

Open the BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING industry page for the award list under the headline. Compare 325414 with 325412 and with biotech R&D codes on All industries. Cite obligations, not outlays, and keep the 1,275 award count with the dollar figure.

Citing biologics manufacturing without R&D or pills

Cite $26,909,128,047.49 in USAspending obligations on 1,275 awards tagged NAICS 325414, biological product except diagnostic manufacturing. Keep except diagnostic in the name. Finished-dose chemical drugs and biotech R&D are other codes.

The 1,275 award count is concentrated production contracting, not doses. This page is not medical advice. Outlays and grants are not in the packet. If a countermeasure buy was tagged 325412 instead, it will not appear here. The industry page is the award list under the $26.9 billion headline.

Biologics manufacturing except diagnostics is vaccines, blood fractions, and similar products as tagged 325414. The $26,909,128,047.49 total sits on only 1,275 awards, a concentrated production pattern rather than a pharmacy delivery-order firehose. A stockpile contract and a supply contract can share the count. Doses are not in the packet.

Research tagged 541711 or 541714 is not manufacturing. Chemical finished-dose drugs tagged 325412 are not this line. Diagnostic products are excepted by the title. This page is not medical advice. Cite USAspending obligations on 1,275 awards coded 325414. Keep outlays out. Keep grants out when they lack NAICS.

Questions

How much is obligated on NAICS 325414 biological products?

USAspending.gov contract awards coded NAICS 325414 show $26,909,128,047.49 in obligations across 1,275 awards. That total is obligations, not outlays, for biological product (except diagnostic) manufacturing. USAspending.gov records the amount as contract obligations, not outlays, on awards tagged NAICS 325414.

Is this the same as pharmaceutical preparation manufacturing?

No. Finished-dose pharmaceutical preparations are NAICS 325412. 325414 is biological products except diagnostics. The $26,909,128,047.49 figure is 325414 only. The packet total is $26,909,128,047.49 across 1,275 awards; assistance awards often have no NAICS and stay outside the industry rollup.

Does 325414 include biotech research contracts?

Biotechnology R&D uses NAICS 541711 and 541714. This table is manufacturing of biological products. Research dollars tagged to those R&D codes are not inside this total. Treat the 1,275 figure as an award-record count, including orders and modifications, not as a physical inventory of products or sites.

Do 1,275 awards mean 1,275 vaccines?

No. The 1,275 figure counts contract award records, including production lots and modifications. It is not a product or dose count. This guide does not add a fiscal-year split. Quote the live industry page if you need the current award list under BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING.